Literature DB >> 11896580

Recurrent allelic deletions at mouse chromosomes 4 and 14 in Myc-induced liver tumors.

Yuanfei Wu1, Claire-Angélique Renard, Françoise Apiou, Michel Huerre, Pierre Tiollais, Bernard Dutrillaux, Marie Annick Buendia.   

Abstract

Transgenic mice expressing the c-Myc oncogene driven by woodchuck hepatitis virus (WHV) regulatory sequences develop hepatocellular carcinoma with a high frequency. To investigate genetic lesions that cooperate with Myc in liver carcinogenesis, we conducted a genome-wide scan for loss of heterozygosity (LOH) and mutational analysis of beta-catenin in 37 hepatocellular adenomas and carcinomas from C57BL/6 x castaneus F1 transgenic mice. In a subset of these tumors, chromosome imbalances were examined by comparative genomic hybridization (CGH). Allelotyping with 99 microsatellite markers spanning all autosomes revealed allelic imbalances at one or more chromosomes in 83.8% of cases. The overall fractional allelic loss was rather low, with a mean index of 0.066. However, significant LOH rates involved chromosomes 4 (21.6% of tumors), 14, 9 and 1 (11 to 16%). Interstitial LOH on chromosome 4 was mapped at band C4-C7 that contains the INK4a/ARF and INK4b loci, and on chromosome 14 at band B-D including the RB locus. In man, the homologous chromosomal regions 9p21, 13q14 and 8p21-23 are frequently deleted in liver cancer. LOH at chromosomes 1 and 14, and beta-catenin mutations (12.5% of cases) were seen only in HCCs. All tumors examined were found to be aneuploid. CGH analysis of 10 representative cases revealed recurrent gains at chromosomes 16 and 19, but losses or deletions involving mostly chromosomes 4 and 14 generally prevailed over gains. Thus, Myc activation in the liver might select for inactivation of tumor suppressor genes on regions of chromosomes 4 and 14 in a context of low genomic instability. Myc transgenic mice provide a useful model for better defining crosstalks between oncogene and tumor suppressor pathways in liver tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11896580     DOI: 10.1038/sj.onc.1205208

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  12 in total

1.  Astrocyte elevated gene-1 and c-Myc cooperate to promote hepatocarcinogenesis in mice.

Authors:  Jyoti Srivastava; Ayesha Siddiq; Rachel Gredler; Xue-Ning Shen; Devaraja Rajasekaran; Chadia L Robertson; Mark A Subler; Jolene J Windle; Catherine I Dumur; Nitai D Mukhopadhyay; Dawn Garcia; Zhao Lai; Yidong Chen; Uthra Balaji; Paul B Fisher; Devanand Sarkar
Journal:  Hepatology       Date:  2015-01-23       Impact factor: 17.425

2.  MYC protein inhibits transcription of the microRNA cluster MC-let-7a-1~let-7d via noncanonical E-box.

Authors:  Zifeng Wang; Sheng Lin; Julia Jun Li; Zhenhua Xu; Hong Yao; Xiao Zhu; Dan Xie; Zan Shen; Johnny Sze; Kui Li; Gang Lu; Danny Tat-Ming Chan; Wai Sang Poon; Hsiang-fu Kung; Marie Chia-mi Lin
Journal:  J Biol Chem       Date:  2011-09-08       Impact factor: 5.157

3.  MYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism.

Authors:  Hirofumi Akita; Jens U Marquardt; Marian E Durkin; Mitsuteru Kitade; Daekwan Seo; Elizabeth A Conner; Jesper B Andersen; Valentina M Factor; Snorri S Thorgeirsson
Journal:  Cancer Res       Date:  2014-09-04       Impact factor: 12.701

4.  Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis.

Authors:  Joanne W Jang; Robert B Boxer; Lewis A Chodosh
Journal:  Mol Cell Biol       Date:  2006-08-14       Impact factor: 4.272

Review 5.  SGF29 and Sry pathway in hepatocarcinogenesis.

Authors:  Nobuya Kurabe; Shigekazu Murakami; Fumio Tashiro
Journal:  World J Biol Chem       Date:  2015-08-26

6.  Recurrent and nonrandom DNA copy number and chromosome alterations in Myc transgenic mouse model for hepatocellular carcinogenesis: implications for human disease.

Authors:  Drazen B Zimonjic; Veronika Ullmannova-Benson; Valentina M Factor; Snorri S Thorgeirsson; Nicholas C Popescu
Journal:  Cancer Genet Cytogenet       Date:  2009-05

7.  Nuclear receptor hepatocyte nuclear factor 4alpha1 competes with oncoprotein c-Myc for control of the p21/WAF1 promoter.

Authors:  Wendy W Hwang-Verslues; Frances M Sladek
Journal:  Mol Endocrinol       Date:  2007-09-20

8.  The role of AEG-1 in the development of liver cancer.

Authors:  Chadia L Robertson; Jyoti Srivastava; Devaraja Rajasekaran; Rachel Gredler; Maaged A Akiel; Nidhi Jariwala; Ayesha Siddiq; Luni Emdad; Paul B Fisher; Devanand Sarkar
Journal:  Hepat Oncol       Date:  2015

9.  FOXN3 Regulates Hepatic Glucose Utilization.

Authors:  Santhosh Karanth; Erin K Zinkhan; Jonathon T Hill; H Joseph Yost; Amnon Schlegel
Journal:  Cell Rep       Date:  2016-06-09       Impact factor: 9.423

10.  Germline Mutations in Mtap Cooperate with Myc to Accelerate Tumorigenesis in Mice.

Authors:  Yuwaraj Kadariya; Baiqing Tang; Liqun Wang; Tahseen Al-Saleem; Kyoko Hayakawa; Michael J Slifker; Warren D Kruger
Journal:  PLoS One       Date:  2013-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.